3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
202
Carcinoma, Renal Cell
68
Liver Neoplasms
61
Neoplasms
53
Neoplasm Metastasis
34
Leukemia, Myeloid, Acute
34
Carcinoma, Non-Small-Cell Lung
32
Breast Neoplasms
29
Melanoma
24
Kidney Neoplasms
21
Pancreatic Neoplasms
16
Brain Neoplasms
15
Sarcoma
14
Prostatic Neoplasms
14
Lung Neoplasms
14
Recurrence
13
Glioblastoma
13
Thyroid Neoplasms
11
Colorectal Neoplasms
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Carcinoma
10
Urinary Bladder Neoplasms
8
Rectal Neoplasms
8
Ovarian Neoplasms
8
Myelodysplastic Syndromes
8
Multiple Myeloma
8
Gliosarcoma
8
Stomach Neoplasms
7
Colonic Neoplasms
7
Unspecified Adult Solid Tumor, Protocol Specific
6
Interventions
pembrolizumab
2
Docetaxel
2
Cisplatin
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
taxane
1
liposomal doxorubicin
1
durvalumab
1
cemiplimab
1
atezolizumab
1
Sorafenib
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Irinotecan
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Drug Therapy
1
Biosimilar Pharmaceuticals
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Vaccinia
×
Sorafenib
×
Clear all
NCT02562755
2020-12-16
PHOCUS
SillaJen, Inc.
Phase 3
Completed
459 enrolled
12 charts